My new favorite company |
I also had an awesome run on Saturday. I had planned on 16 miles, and after the first 5-mile turnaround, I found myself running alongside a pack of girls who were actually running my pace. My new friend Amanda convinced me to stick out another 2 miles with her, which I did, finishing an 18-mile run with an average pace under 7:40/mile. Six weeks ago I was hardly running at all and still in PT for my hip-- so I was feeling pretty good with this run.
I'm very appreciative of my experiences this past weekend. The people at Saucony made me realize that many people are willing to give money towards this cause, so long as someone simply asks them. My run with Amanda reminded me that I'm a pretty good runner, and that all of this effort is not only relevant to the stories of my own friends and family, but to a lot of others as well.
Everyone I've met running with Dana-Farber, like Paula and Amanda, have had similar stories about the ways in which they've been impacted by cancer. Few have said "I wanted to run the Boston Marathon and DFMC was my ticket into the race." I heard from two different people on Saturday that they recently lost someone, almost suddenly, due to pancreatic cancer. I've spoken a lot about melanoma and prostate cancer, because of my high risk, but I knew nothing about cancer of the pancreas, so I figured I'd take a look at what the Claudia Adams Barr Program has been doing in this realm.
I found something pretty interesting: it's apparently been discovered that an anti-malarial drug called hydroxychloroquine is effective in shrinking or slowing the growth of pancreatic cancers:
Hydroxychloroquine is a drug that inhibits “autophagy,” a process that enables cells to break down and eliminate structures such as damaged cell membranes. Cancer cells use autophagy to outwit chemotherapy treatment: by activating this process they survive the stress of therapy. Alec Kimmelman, MD, PHD, with Barr Program support in 2009-‘10 discovered that autophagy is turned on all at all times in pancreatic cancer cells suggesting that pancreas tumors are highly dependent on autophagy and therefore good candidates for autophagy-inhibiting treatments. Testing with mice treated with the drug, the treatments were found to be very effective and Dr. Kimmelman plans to move to human trials soon.
I strongly believe in the mission and impact of the DFMC team. In my last post, I wrote about how much I enjoy running, and I am certainly excited about running the Boston Marathon-- but that's not why I'm running for DFMC. I'm part of this team because I wanted to do something to raise awareness, and money, for the fight against cancer.
With that being said, I've decided I won't be satisfied by hitting my goal of $6500, which I expect to surpass well before Marathon Monday. I've raised my fundraising goal to $8000 and with your help, I'll get there.
With that being said, I've decided I won't be satisfied by hitting my goal of $6500, which I expect to surpass well before Marathon Monday. I've raised my fundraising goal to $8000 and with your help, I'll get there.
Please donate: http://www.rundfmc.org/2013/jeffl